Yahoo · Oct 23, 2026
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Zoetis (ZTS) closed at $81.03, marking a -1.18% move from the previous day.
NASDAQ · ZTS
Zoetis Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$78.80
Up+$1.45 (+1.85%)
Updated Oct 31, 2026, 1:20 AM
SID Score
6.1/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 51.85B
- P/E ratio
- 19.66
- Dividend yield
- 2.54%
- 52-week range
- $68.77 – $132.49
- Volume
- 2.94M
- Avg. volume
- 4.62M
Price performance · ZTS
ZTS price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
ZTS closed at $78.80 after 20 trading sessions, up 13.07% for the selected period.
- Last close
- $78.80
- Period change
- +13.07%
- Period low
- $69.69
- Period high
- $82.00
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $78.44 | $79.2805 | $77.76 | $78.80 | 2.94M |
| Oct 28, 2026 | $77.355 | $78.555 | $77.03 | $77.80 | 2.62M |
| Oct 27, 2026 | $80.59 | $80.59 | $78.065 | $78.23 | 2.83M |
| Oct 26, 2026 | $80.95 | $81.19 | $80.10 | $80.97 | 2.9M |
| Oct 23, 2026 | $81.14 | $81.86 | $80.6001 | $81.03 | 2.86M |
| Oct 22, 2026 | $79.90 | $82.29 | $79.90 | $82.00 | 4.83M |
| Oct 21, 2026 | $79.22 | $80.00 | $78.88 | $79.62 | 3.04M |
| Oct 20, 2026 | $79.64 | $80.25 | $79.03 | $80.04 | 3.74M |
| Oct 19, 2026 | $78.85 | $79.98 | $78.4501 | $79.59 | 3.07M |
| Oct 16, 2026 | $78.29 | $80.59 | $78.29 | $79.38 | 5.57M |
| Oct 15, 2026 | $76.70 | $79.15 | $76.52 | $78.42 | 5.02M |
| Oct 14, 2026 | $74.54 | $75.8919 | $74.25 | $75.29 | 4.16M |
| Oct 13, 2026 | $75.98 | $75.99 | $74.28 | $74.30 | 3.3M |
| Oct 12, 2026 | $75.00 | $75.69 | $74.17 | $75.65 | 4.09M |
| Oct 9, 2026 | $73.04 | $74.85 | $73.00 | $74.81 | 2.91M |
| Oct 8, 2026 | $71.36 | $73.75 | $71.15 | $73.08 | 6.18M |
| Oct 7, 2026 | $71.73 | $72.09 | $71.115 | $71.55 | 4.13M |
| Oct 6, 2026 | $71.88 | $72.30 | $70.59 | $71.33 | 3.44M |
| Oct 5, 2026 | $69.41 | $71.47 | $69.00 | $71.41 | 3.64M |
| Oct 2, 2026 | $69.12 | $70.10 | $68.77 | $69.69 | 5.26M |
Latest ZTS news
The latest Smart Investors Daily articles mentioning ZTS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ZTS research
Overview
Company profile and research snapshot.
Company profile
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $157.80
- Implied upside
- —
- Analysts
- 17
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | Morgan Stanley | Overweight | — |
| Oct 27, 2026 | UBS | Neutral | — |
| Oct 20, 2026 | Jefferies | Hold | — |
| Oct 16, 2026 | Goldman Sachs | Neutral | — |
| Aug 25, 2026 | TD Cowen | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 20, 2026
Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
PARSIPPANY, N.J., October 20, 2026--Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections
SeekingAlpha · Oct 20, 2026
Zoetis: Weakening Fundamentals Overshadow The Discount
Zoetis (ZTS) rated sell as growth slows and guidance falls. Read the latest analysis on the stock here.
Benzinga · Oct 20, 2026
FDA Approves Ready-To-Use Cefovecin Injectable For Treatment Of Certain Skin Infections In Dogs
https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-ready-use-cefovecin-injectable-treatment-certain-skin-infections-dogs
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
